These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Patients with ROS1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy. Song Z, Su H, Zhang Y. Cancer Med; 2016 Oct; 5(10):2688-2693. PubMed ID: 27544536 [Abstract] [Full Text] [Related]
28. [Correlation between common driver gene variations and clinicopathological typing in lung adenocarcinoma]. Ma XL, Jia RN, Han K, Zhang YX. Zhonghua Bing Li Xue Za Zhi; 2024 Jun 08; 53(6):578-584. PubMed ID: 38825903 [Abstract] [Full Text] [Related]
30. Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements. Cha YJ, Lee JS, Kim HR, Lim SM, Cho BC, Lee CY, Shim HS. PLoS One; 2014 Jun 08; 9(7):e103333. PubMed ID: 25058391 [Abstract] [Full Text] [Related]
31. Histopathologic characteristics of advanced-stage ROS1-rearranged non-small cell lung cancers. Park E, Choi YL, Ahn MJ, Han J. Pathol Res Pract; 2019 Jul 08; 215(7):152441. PubMed ID: 31085007 [Abstract] [Full Text] [Related]
32. Immunocytochemical Detection of ALK and ROS1 Rearrangements in Lung Cancer Cytological Samples. Frankel D, Kaspi E, Roll P. Methods Mol Biol; 2021 Jul 08; 2279():157-164. PubMed ID: 33683692 [Abstract] [Full Text] [Related]